DK3347006T3 - Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf - Google Patents

Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf Download PDF

Info

Publication number
DK3347006T3
DK3347006T3 DK16769437.1T DK16769437T DK3347006T3 DK 3347006 T3 DK3347006 T3 DK 3347006T3 DK 16769437 T DK16769437 T DK 16769437T DK 3347006 T3 DK3347006 T3 DK 3347006T3
Authority
DK
Denmark
Prior art keywords
etifoxin
derivatives
deuterated analogues
deuterated
analogues
Prior art date
Application number
DK16769437.1T
Other languages
English (en)
Inventor
Olivier Dasse
Original Assignee
Gaba Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gaba Therapeutics Inc filed Critical Gaba Therapeutics Inc
Application granted granted Critical
Publication of DK3347006T3 publication Critical patent/DK3347006T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK16769437.1T 2015-03-20 2016-03-18 Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf DK3347006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135979P 2015-03-20 2015-03-20
PCT/US2016/023231 WO2016154039A1 (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof

Publications (1)

Publication Number Publication Date
DK3347006T3 true DK3347006T3 (da) 2022-10-17

Family

ID=56977741

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16769437.1T DK3347006T3 (da) 2015-03-20 2016-03-18 Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf

Country Status (20)

Country Link
US (4) US10080755B2 (da)
EP (1) EP3347006B1 (da)
JP (3) JP6762507B2 (da)
KR (1) KR102290766B1 (da)
CN (1) CN107530323B (da)
AU (2) AU2016235495B2 (da)
BR (1) BR112017020081B1 (da)
CA (1) CA2979853C (da)
DK (1) DK3347006T3 (da)
ES (1) ES2928396T3 (da)
HR (1) HRP20221240T1 (da)
HU (1) HUE060240T2 (da)
IL (2) IL270627B2 (da)
LT (1) LT3347006T (da)
MX (1) MX2017011978A (da)
PL (1) PL3347006T3 (da)
PT (1) PT3347006T (da)
RS (1) RS63654B1 (da)
SI (1) SI3347006T1 (da)
WO (1) WO2016154039A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3347006T (pt) * 2015-03-20 2022-10-17 Gaba Therapeutics Inc Análogos deuterados de etifoxina, os seus derivados e suas utilizações
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
CN111902139A (zh) * 2018-03-23 2020-11-06 康塞特医药品有限公司 氘代的D-β-羟基丁酸的类似物及其用途
WO2019222581A1 (en) * 2018-05-18 2019-11-21 Ovid Therapeutics Inc. Methods of treating attention deficit hyperactivity disorder
CN112125862A (zh) * 2019-06-25 2020-12-25 上海安谱实验科技股份有限公司 一种稳定同位素标记的阿特拉津-d5及其合成方法
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
WO2023218251A1 (en) * 2022-05-10 2023-11-16 Clearsynth Labs Limied Novel deuterium-enriched nefazodone analogues and method for preparing thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670772C3 (de) 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
FR2888748B1 (fr) 2005-07-19 2007-10-12 Biocodex Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
US8110569B2 (en) 2006-03-20 2012-02-07 The Regents Of The University Of California Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2007109288A2 (en) * 2006-03-20 2007-09-27 Xytis Inc. Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
NZ606587A (en) * 2010-07-09 2015-03-27 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
JP5193400B2 (ja) * 2011-07-05 2013-05-08 公益財団法人乙卯研究所 重水素化フェニルプロピオン酸誘導体
FR3016881B1 (fr) 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
PT3347006T (pt) * 2015-03-20 2022-10-17 Gaba Therapeutics Inc Análogos deuterados de etifoxina, os seus derivados e suas utilizações

Also Published As

Publication number Publication date
BR112017020081B1 (pt) 2021-11-30
AU2020201728A1 (en) 2020-03-26
JP2021001174A (ja) 2021-01-07
PL3347006T3 (pl) 2022-11-14
EP3347006A1 (en) 2018-07-18
EP3347006A4 (en) 2019-04-24
IL254567B (en) 2020-03-31
JP6762507B2 (ja) 2020-09-30
CA2979853C (en) 2021-05-11
US11672805B2 (en) 2023-06-13
KR102290766B1 (ko) 2021-08-19
AU2016235495A1 (en) 2017-10-05
AU2016235495B2 (en) 2020-05-14
BR112017020081A2 (pt) 2018-06-05
IL270627B (en) 2022-11-01
HUE060240T2 (hu) 2023-02-28
ES2928396T3 (es) 2022-11-17
PT3347006T (pt) 2022-10-17
US10080755B2 (en) 2018-09-25
CN107530323A (zh) 2018-01-02
MX2017011978A (es) 2018-02-09
LT3347006T (lt) 2022-10-25
US20200405726A1 (en) 2020-12-31
JP2018508592A (ja) 2018-03-29
WO2016154039A1 (en) 2016-09-29
SI3347006T1 (sl) 2022-11-30
US20230263805A1 (en) 2023-08-24
AU2020201728B2 (en) 2021-12-23
HRP20221240T1 (hr) 2022-12-09
IL254567A0 (en) 2017-11-30
JP2023009114A (ja) 2023-01-19
JP7376668B2 (ja) 2023-11-08
US20190015419A1 (en) 2019-01-17
RS63654B1 (sr) 2022-11-30
CA2979853A1 (en) 2016-09-29
US20180064717A1 (en) 2018-03-08
IL270627A (da) 2019-12-31
KR20170137085A (ko) 2017-12-12
US10736901B2 (en) 2020-08-11
EP3347006B1 (en) 2022-07-27
CN107530323B (zh) 2021-05-04
IL270627B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
DK3872085T3 (da) Stam-virussekvenser og anvendelser heraf
DK3371171T3 (da) Inhibitorer af RET
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3154594T3 (da) Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed
DK3359241T3 (da) Formuleringer af pthrp-analoger, transdermale plastre deraf og anvendelser deraf
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3347006T3 (da) Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3307267T3 (da) Behandling af multipel sklerose
DK3390422T3 (da) Krystalformer af lnt
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3265126T3 (da) Kombinationsformulering af tesofensin og metoprolol
DK3436434T3 (da) Indolin-analoger og anvendelser deraf
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3256479T3 (da) 4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3273821T3 (da) Tilpasseligt smykke